Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. Foresee Pharmaceuticals Co., Ltd. was incorporated in 2013 and is based in Taipei, Taiwan.
तुलना करने के लिए मीट्रिक्स | 6576 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध6576पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −7.8x | −13.6x | −0.5x | |
PEG अनुपात | 0.41 | 0.10 | 0.00 | |
क़ीमत/बुक | 7.4x | 2.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 23.1x | 5.1x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 99.2% | 0.0% | 53.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | −3.3% | 8.4% | अनलॉक करें |